Found 6 hits in this display Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kJ/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Mitogen-activated protein kinase kinase kinase 5
(Homo sapiens (Human)) | BDBM307648
(2-(6-(4-cyclopropyl- 4H-1,2,4-triazol-3- yl)pyridi...)Show SMILES O=C1N(Cc2ccc(cc12)-c1cccnc1)c1cccc(n1)-c1nncn1C1CC1 Show InChI InChI=1S/C23H18N6O/c30-23-19-11-15(16-3-2-10-24-12-16)6-7-17(19)13-28(23)21-5-1-4-20(26-21)22-27-25-14-29(22)18-8-9-18/h1-7,10-12,14,18H,8-9,13H2 | PDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet 
| PC cid
PC sid
UniChem
| US Patent
| <200 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
SEAL ROCK THERAPEUTICS, INC.
US Patent
| Assay Description
The ASK1 enzymatic assay was run following Promega ASK1 Kinase Enzyme System (Cat #V3881). The kit provides the protocol, enzymes and all reagents ne... |
US Patent US10150755 (2018)
BindingDB Entry DOI: 10.7270/Q2125VQ8 |
More data for this
Ligand-Target Pair | |
Myosin light chain kinase, smooth muscle
(Homo sapiens (Human)) | BDBM307648
(2-(6-(4-cyclopropyl- 4H-1,2,4-triazol-3- yl)pyridi...)Show SMILES O=C1N(Cc2ccc(cc12)-c1cccnc1)c1cccc(n1)-c1nncn1C1CC1 Show InChI InChI=1S/C23H18N6O/c30-23-19-11-15(16-3-2-10-24-12-16)6-7-17(19)13-28(23)21-5-1-4-20(26-21)22-27-25-14-29(22)18-8-9-18/h1-7,10-12,14,18H,8-9,13H2 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| <200 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
SEAL ROCK THERAPEUTICS, INC.
US Patent
| Assay Description
MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w... |
US Patent US10150755 (2018)
BindingDB Entry DOI: 10.7270/Q2125VQ8 |
More data for this
Ligand-Target Pair | |
Mitogen-activated protein kinase kinase kinase 5
(Homo sapiens (Human)) | BDBM307648
(2-(6-(4-cyclopropyl- 4H-1,2,4-triazol-3- yl)pyridi...)Show SMILES O=C1N(Cc2ccc(cc12)-c1cccnc1)c1cccc(n1)-c1nncn1C1CC1 Show InChI InChI=1S/C23H18N6O/c30-23-19-11-15(16-3-2-10-24-12-16)6-7-17(19)13-28(23)21-5-1-4-20(26-21)22-27-25-14-29(22)18-8-9-18/h1-7,10-12,14,18H,8-9,13H2 | PDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <200 | n/a | n/a | n/a | n/a | n/a | n/a |
SEAL ROCK THERAPEUTICS, INC.
US Patent
| Assay Description
The ASK1 enzymatic assay was run following Promega ASK1 Kinase Enzyme System (Cat #V3881). The kit provides the protocol, enzymes and all reagents ne... |
US Patent US10150755 (2018)
BindingDB Entry DOI: 10.7270/Q27P91GS |
More data for this
Ligand-Target Pair | |
Tumor necrosis factor
(Homo sapiens (Human)) | BDBM307648
(2-(6-(4-cyclopropyl- 4H-1,2,4-triazol-3- yl)pyridi...)Show SMILES O=C1N(Cc2ccc(cc12)-c1cccnc1)c1cccc(n1)-c1nncn1C1CC1 Show InChI InChI=1S/C23H18N6O/c30-23-19-11-15(16-3-2-10-24-12-16)6-7-17(19)13-28(23)21-5-1-4-20(26-21)22-27-25-14-29(22)18-8-9-18/h1-7,10-12,14,18H,8-9,13H2 | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <200 | n/a | n/a | n/a | n/a | n/a | n/a |
SEAL ROCK THERAPEUTICS, INC.
US Patent
| Assay Description
Cryopreserved human PBMCs were obtained from AllCells (cat# PB003F). After thawing/dilution protocols using RPMI medium supplemented with 5% FBS (hea... |
US Patent US10150755 (2018)
BindingDB Entry DOI: 10.7270/Q2125VQ8 |
More data for this
Ligand-Target Pair | |
Tumor necrosis factor
(Homo sapiens (Human)) | BDBM307648
(2-(6-(4-cyclopropyl- 4H-1,2,4-triazol-3- yl)pyridi...)Show SMILES O=C1N(Cc2ccc(cc12)-c1cccnc1)c1cccc(n1)-c1nncn1C1CC1 Show InChI InChI=1S/C23H18N6O/c30-23-19-11-15(16-3-2-10-24-12-16)6-7-17(19)13-28(23)21-5-1-4-20(26-21)22-27-25-14-29(22)18-8-9-18/h1-7,10-12,14,18H,8-9,13H2 | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <2.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
SEAL ROCK THERAPEUTICS, INC.
US Patent
| Assay Description
Cryopreserved human PBMCs were obtained from AllCells (cat# PB003F). After thawing/dilution protocols using RPMI medium supplemented with 5% FBS (hea... |
US Patent US10150755 (2018)
BindingDB Entry DOI: 10.7270/Q27P91GS |
More data for this
Ligand-Target Pair | |
Myosin light chain kinase, smooth muscle
(Homo sapiens (Human)) | BDBM307648
(2-(6-(4-cyclopropyl- 4H-1,2,4-triazol-3- yl)pyridi...)Show SMILES O=C1N(Cc2ccc(cc12)-c1cccnc1)c1cccc(n1)-c1nncn1C1CC1 Show InChI InChI=1S/C23H18N6O/c30-23-19-11-15(16-3-2-10-24-12-16)6-7-17(19)13-28(23)21-5-1-4-20(26-21)22-27-25-14-29(22)18-8-9-18/h1-7,10-12,14,18H,8-9,13H2 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a |
SEAL ROCK THERAPEUTICS, INC.
US Patent
| Assay Description
MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w... |
US Patent US10150755 (2018)
BindingDB Entry DOI: 10.7270/Q27P91GS |
More data for this
Ligand-Target Pair | |